Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis
Rattachement africain : de, gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE: Due to significantly lower neurocognitive toxicity, whole-brain irradiation (WBI) has largely been replaced by focal irradiation of the resection cavity following brain metastasis surgery. However, the optimal treatment modality and fractionation scheme remain controversial. This study conducts a comparative analysis of hypofractionated stereotactic radiotherapy (HSRT) and intraoperative radiotherapy (IORT), focusing on clinical outcomes and toxicity profiles. METHODS: A retrospective cohort study was conducted, analyzing 129 patients (HSRT: 72, IORT: 57) with 137 treated cavities (HSRT: 75, IORT: 62) at the University Hospital of Augsburg (UKA) between 2013 and 2021. Baseline characteristics, oncological outcomes, incidence of radionecrosis (RN), and time to further treatment were compared. RESULTS: Radionecrosis occurred significantly less frequently in the IORT group compared to HSRT, with 1-year RN rates of 3.7% (95% CI: 0.5-23.5%) and 21.8% (95% CI: 11.7-39.2%), respectively (p = 0.00025). At two years, the RN rate remained substantially lower after IORT (8.5% vs. 53.2%). Notably, in patients without prior cerebral irradiation, no symptomatic RN (sRN) occurred following IORT, whereas the 2-year sRN rate in the HSRT group reached 35.5% (p = 0.0036). Oncological outcomes, including overall survival (OS), local control (LC), intracranial disease control, leptomeningeal dissemination (LMD), and WBI avoidance, were comparable between the two groups. However, distant brain control (DBC) at one year was higher in the HSRT group. While HSRT was initiated after a median delay of 29 days (range: 14-71), IORT was delivered intraoperatively, enabling immediate continuation of systemic therapy. CONCLUSION: In this retrospective single-center analysis, IORT demonstrated comparable oncological efficacy to HSRT while significantly reducing the risk of RN. Given its intraoperative delivery and the ability to promptly resume systemic therapy, and the precise application directly at the resection cavity, IORT may represent a practical and effective alternative in selected patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis
- Date Crossref
- 13/08/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Augsburg pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Augsburg pays non établi dans la noticeÉtablissement de santé
-
London Cancer pays non établi dans la noticeInstitution
-
Medizinische Universität Lausitz - Carl Thiem pays non établi dans la noticeÉtablissement de santé
-
Augsburg University pays non établi dans la noticeUniversité ou école supérieure
-
Bavarian Cancer Research Center (BZKF) pays non établi dans la noticeStructure de recherche
-
Comprehensive Cancer Center Alliance WERA (CCC WERA) pays non établi dans la noticeInstitution
-
Faculty of Medicine Comprehensive Cancer Center Augsburg (CCCA) pays non établi dans la noticeUniversité ou école supérieure
-
Lausitz University Hospital Department of Neurosurgery pays non établi dans la noticeUniversité ou école supérieure
-
Klinik für Strahlentherapie und Radioonkologie pays non établi dans la noticeInstitution
University of Augsburg, University Hospital Augsburg et London Cancer, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.